# Vanderbilt Network Lead Academic Participating Site for the NCTN

> **NIH NIH UG1** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2020 · $487,276

## Abstract

PROJECT SUMMARY/ABSTRACT
Vanderbilt-Ingram Cancer Center (VICC) is a matrix cancer center within Vanderbilt University Medical Center
(VUMC). VICC has been part of the cooperative group system for over 27 years, and a Lead Academic
Participating Site since the inception of the National Clinical Trials Network (NCTN). Throughout the years, we
have integrated our physicians into leadership roles and our basic science into investigator-initiated trials, as
well as enrolled patients onto clinical trials. Additionally, VICC has a long track record of leadership, both
scientific and administrative, within the cooperative groups/NCTN, and helping junior faculty in clinical trial
development. VICC brings great strengths to the NCTN, including two SPORE grants, an EDRN grant, a world
class Institute of Imaging Science, eight highly funded scientific programs and an Early Therapeutics Clinical
Trial Network (ETCTN) grant where successful early phase trials can be integrated into the NCTN. Our
Personalized Cancer Medicine Initiative (PCMI) is dedicated to matching the appropriate therapy to the genetic
changes, or mutations, that are driving the growth of cancers, with an active research component investigating
mechanisms of resistance to targeted therapies. The key informatics of the VICC PCMI is MyCancerGenome,
a website that not only informs physicians on the latest in cancer genomics, but also the availability of trials for
patients whose tumors harbor actionable genetic alterations. With the development of PD-1/PD-L1 inhibitors
and novel immune therapies on the horizon, VICC has recruited top researchers in immunology. Those top
researchers in collaboration with other VUMC investigators created the Vanderbilt Institute for Infection,
Immunology and Inflammation (VI4) with an overall mission to train the next generation scientists and
physicians and make fundamental discoveries in the areas of infection biology, immunology and inflammation
with the goal of increasing knowledge and improving human health. VICC clinicians and scientists are
academic leaders in their respective disciplines and will continue to significantly contribute to the NCTN goals
with the objective to improve the outcomes for cancer patients.
The VICC selected Dr. Jordan Berlin, MD, as Principal Investigator to continue leading the efforts of the
institution to integrate its scientific, academic and patient resources into the NCTN. He has been involved
extensively in the cooperative groups/NCTN in conduct of clinical trials, mentorship and leadership. To assist
Dr. Berlin with the conduct of this grant, VICC created two advisory boards, Internal Advisory Board (IAB) and
NCTN Executive Committee (NEC), whose membership includes a broad representation of medical disciplines
and disease interests across VICC and VUMC. The IAB assures the optimal use of the grant, such as budget
review, assuring multidisciplinary involvement, and participation throughout the NCTN. The NEC implements
oper...

## Key facts

- **NIH application ID:** 9889083
- **Project number:** 5UG1CA233270-02
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** JORDAN D BERLIN
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $487,276
- **Award type:** 5
- **Project period:** 2019-03-07 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9889083

## Citation

> US National Institutes of Health, RePORTER application 9889083, Vanderbilt Network Lead Academic Participating Site for the NCTN (5UG1CA233270-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9889083. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*